NEWARK, Del, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market, valued at USD 2,669.1 million in 2024, is estimated to grow at a compound annual growth rate (CAGR ...
NEWARK, Del, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market, valued at USD 2,669.1 million in 2024, is estimated to grow at a compound annual growth rate (CAGR) of ...
UMB Bank n.a. increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 260.1% in the 4th ...
GlobalData on MSN9d
Regenxbio and Nippon Shinyaku forge $810m gene therapy dealRegenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...
Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a ...
Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...
It is a recessive X-linked disease, which means mothers have a 50 per cent chance of passing it to their sons. It is rare and ...
REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for ...
REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...
Haliza Md Kasim’s eyes widened. Despite having gone through this before with her first son, Yusof, and despite the doctors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback